ESMO Media Releases

Pain relief and other forms of supportive care for cancer patients are insufficient, researchers will report at the ESMO Asia 2016 Congress

Research to be presented at the ESMO Asia 2016 Congress

The ESMO Asia 2016 Congress announces its press programme today. The meeting brings together cancer experts in Singapore, from 16 to 19 December 2016

Late registration for ESMO Asia 2016 Congress ends 9 November

The 4th edition of the ESMO Symposium on Immuno-Oncology begins Friday 4 November 2016 in Lausanne, Switzerland

ESMO 2016 Congress has broken records, not only of attendance, but in terms of the quality science being presented, that will impact the practice of oncology

A phase III trial of sunitinib has met its primary endpoint of disease-free survival for adjuvant treatment of high-risk renal cell carcinoma after nephrectomy, researchers report at the ESMO 2016 Congress in Copenhagen.

Neoadjuvant chemotherapy with an anthracycline plus ifosfamide was associated with significant survival gains in patients with soft tissue sarcoma of the trunk or extremities who are at high-risk of recurrence, in an interim analysis that led to the early discontinuation of a trial presented today at the ESMO 2016 Congress in Copenhagen.

A phase III randomized controlled trial of custirsen in combination with cabazitaxel/prednisone in patients with previously-treated metastatic, castration-resistant prostate cancer has shown no significant survival gains compared to cabazitaxel/prednisone alone, according to data presented at the ESMO 2016 Congress in Copenhagen.

MEK inhibitor selumetinib in combination with docetaxel does not improve progression free or overall survival in individuals with KRAS-mutant non-small-cell lung cancer (NSCLC), according to data presented at the ESMO 2016 Congress in Copenhagen.

Cabozantinib significantly improves progression-free survival and response rate in patients with metastatic renal cell carcinoma compared to sunitinib, according to research presented today at the ESMO 2016 Congress in Copenhagen.

The results of the first study analysing the application of the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) in a real-life context for rare tumour entities, were announced today at the ESMO 2016 Congress in Copenhagen.